Philippe Laflamme
McGill University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Philippe Laflamme.
Nature Genetics | 2007
Brent W. Zanke; Celia M. T. Greenwood; Jagadish Rangrej; Rafal Kustra; Albert Tenesa; Susan M. Farrington; James Prendergast; Sylviane Olschwang; Theodore Chiang; Edgar Crowdy; Vincent Ferretti; Philippe Laflamme; Saravanan Sundararajan; Stéphanie Roumy; Jean François Olivier; Frédérick Robidoux; Robert Sladek; Alexandre Montpetit; Peter J. Campbell; Stéphane Bézieau; Anne Marie O'Shea; George Zogopoulos; Michelle Cotterchio; Polly A. Newcomb; John R. McLaughlin; Ban Younghusband; Roger C. Green; Jane Green; Mary Porteous; Harry Campbell
Using a multistage genetic association approach comprising 7,480 affected individuals and 7,779 controls, we identified markers in chromosomal region 8q24 associated with colorectal cancer. In stage 1, we genotyped 99,632 SNPs in 1,257 affected individuals and 1,336 controls from Ontario. In stages 2–4, we performed serial replication studies using 4,024 affected individuals and 4,042 controls from Seattle, Newfoundland and Scotland. We identified one locus on chromosome 8q24 and another on 9p24 having combined odds ratios (OR) for stages 1–4 of 1.18 (trend; P = 1.41 × 10−8) and 1.14 (trend; P = 1.32 × 10−5), respectively. Additional analyses in 2,199 affected individuals and 2,401 controls from France and Europe supported the association at the 8q24 locus (OR = 1.16, trend; 95% confidence interval (c.i.): 1.07–1.26; P = 5.05 × 10−4). A summary across all seven studies at the 8q24 locus was highly significant (OR = 1.17, c.i.: 1.12–1.23; P = 3.16 × 10−11). This locus has also been implicated in prostate cancer.
International Journal of Epidemiology | 2010
Michael Wolfson; Susan Wallace; Nicholas G. D. Masca; Geoff Rowe; Nuala A. Sheehan; Vincent Ferretti; Philippe Laflamme; Martin D. Tobin; John Macleod; Julian Little; Isabel Fortier; Bartha Maria Knoppers; Paul R. Burton
Background Contemporary bioscience sometimes demands vast sample sizes and there is often then no choice but to synthesize data across several studies and to undertake an appropriate pooled analysis. This same need is also faced in health-services and socio-economic research. When a pooled analysis is required, analytic efficiency and flexibility are often best served by combining the individual-level data from all sources and analysing them as a single large data set. But ethico-legal constraints, including the wording of consent forms and privacy legislation, often prohibit or discourage the sharing of individual-level data, particularly across national or other jurisdictional boundaries. This leads to a fundamental conflict in competing public goods: individual-level analysis is desirable from a scientific perspective, but is prevented by ethico-legal considerations that are entirely valid. Methods Data aggregation through anonymous summary-statistics from harmonized individual-level databases (DataSHIELD), provides a simple approach to analysing pooled data that circumvents this conflict. This is achieved via parallelized analysis and modern distributed computing and, in one key setting, takes advantage of the properties of the updating algorithm for generalized linear models (GLMs). Results The conceptual use of DataSHIELD is illustrated in two different settings. Conclusions As the study of the aetiological architecture of chronic diseases advances to encompass more complex causal pathways—e.g. to include the joint effects of genes, lifestyle and environment—sample size requirements will increase further and the analysis of pooled individual-level data will become ever more important. An aim of this conceptual article is to encourage others to address the challenges and opportunities that DataSHIELD presents, and to explore potential extensions, for example to its use when different data sources hold different data on the same individuals.
International Journal of Epidemiology | 2014
Amadou Gaye; Yannick Marcon; Julia Isaeva; Philippe Laflamme; Andrew Turner; Elinor M. Jones; Joel Minion; Andrew W Boyd; Christopher Newby; Marja-Liisa Nuotio; Rebecca Wilson; Oliver Butters; Barnaby Murtagh; Ipek Demir; Dany Doiron; Lisette Giepmans; Susan Wallace; Isabelle Budin-Ljøsne; Carsten Schmidt; Paolo Boffetta; Mathieu Boniol; Maria Bota; Kim W. Carter; Nick deKlerk; Chris Dibben; Richard W. Francis; Tero Hiekkalinna; Kristian Hveem; Kirsti Kvaløy; Seán R. Millar
Background: Research in modern biomedicine and social science requires sample sizes so large that they can often only be achieved through a pooled co-analysis of data from several studies. But the pooling of information from individuals in a central database that may be queried by researchers raises important ethico-legal questions and can be controversial. In the UK this has been highlighted by recent debate and controversy relating to the UK’s proposed ‘care.data’ initiative, and these issues reflect important societal and professional concerns about privacy, confidentiality and intellectual property. DataSHIELD provides a novel technological solution that can circumvent some of the most basic challenges in facilitating the access of researchers and other healthcare professionals to individual-level data. Methods: Commands are sent from a central analysis computer (AC) to several data computers (DCs) storing the data to be co-analysed. The data sets are analysed simultaneously but in parallel. The separate parallelized analyses are linked by non-disclosive summary statistics and commands transmitted back and forth between the DCs and the AC. This paper describes the technical implementation of DataSHIELD using a modified R statistical environment linked to an Opal database deployed behind the computer firewall of each DC. Analysis is controlled through a standard R environment at the AC. Results: Based on this Opal/R implementation, DataSHIELD is currently used by the Healthy Obese Project and the Environmental Core Project (BioSHaRE-EU) for the federated analysis of 10 data sets across eight European countries, and this illustrates the opportunities and challenges presented by the DataSHIELD approach. Conclusions: DataSHIELD facilitates important research in settings where: (i) a co-analysis of individual-level data from several studies is scientifically necessary but governance restrictions prohibit the release or sharing of some of the required data, and/or render data access unacceptably slow; (ii) a research group (e.g. in a developing nation) is particularly vulnerable to loss of intellectual property—the researchers want to fully share the information held in their data with national and international collaborators, but do not wish to hand over the physical data themselves; and (iii) a data set is to be included in an individual-level co-analysis but the physical size of the data precludes direct transfer to a new site for analysis.
BMC Bioinformatics | 2012
Ivan Borozan; Shane Wilson; Paola Blanchette; Philippe Laflamme; Stuart Watt; Paul M. Krzyzanowski; Fabrice Sircoulomb; Robert Rottapel; Philip E. Branton; Vincent Ferretti
BackgroundIt is now well established that nearly 20% of human cancers are caused by infectious agents, and the list of human oncogenic pathogens will grow in the future for a variety of cancer types. Whole tumor transcriptome and genome sequencing by next-generation sequencing technologies presents an unparalleled opportunity for pathogen detection and discovery in human tissues but requires development of new genome-wide bioinformatics tools.ResultsHere we present CaPSID (Computational Pathogen Sequence IDentification), a comprehensive bioinformatics platform for identifying, querying and visualizing both exogenous and endogenous pathogen nucleotide sequences in tumor genomes and transcriptomes. CaPSID includes a scalable, high performance database for data storage and a web application that integrates the genome browser JBrowse. CaPSID also provides useful metrics for sequence analysis of pre-aligned BAM files, such as gene and genome coverage, and is optimized to run efficiently on multiprocessor computers with low memory usage.ConclusionsTo demonstrate the usefulness and efficiency of CaPSID, we carried out a comprehensive analysis of both a simulated dataset and transcriptome samples from ovarian cancer. CaPSID correctly identified all of the human and pathogen sequences in the simulated dataset, while in the ovarian dataset CaPSID’s predictions were successfully validated in vitro.
Public Health Genomics | 2012
Madeleine Murtagh; Ipek Demir; Kn Jenkings; Susan Wallace; Barnaby Murtagh; Mathieu Boniol; Maria Bota; Philippe Laflamme; Paolo Boffetta; Vincent Ferretti; Paul R. Burton
Contemporary bioscience is seeing the emergence of a new data economy: with data as its fundamental unit of exchange. While sharing data within this new ‘economy’ provides many potential advantages, the sharing of individual data raises important social and ethical concerns. We examine ongoing development of one technology, DataSHIELD, which appears to elide privacy concerns about sharing data by enabling shared analysis while not actually sharing any individual-level data. We combine presentation of the development of DataSHIELD with presentation of an ethnographic study of a workshop to test the technology. DataSHIELD produced an application of the norm of privacy that was practical, flexible and operationalizable in researchers’ everyday activities, and one which fulfilled the requirements of ethics committees. We demonstrated that an analysis run via DataSHIELD could precisely replicate results produced by a standard analysis where all data are physically pooled and analyzed together. In developing DataSHIELD, the ethical concept of privacy was transformed into an issue of security. Development of DataSHIELD was based on social practices as well as scientific and ethical motivations. Therefore, the ‘success’ of DataSHIELD would, likewise, be dependent on more than just the mathematics and the security of the technology.
PubMed | 2012
Madeleine Murtagh; Ipek Demir; Kn Jenkings; Susan Wallace; Barnaby Murtagh; Mathieu Boniol; Maria Bota; Philippe Laflamme; Paolo Boffetta; Ferretti; Paul R. Burton
Contemporary bioscience is seeing the emergence of a new data economy: with data as its fundamental unit of exchange. While sharing data within this new ‘economy’ provides many potential advantages, the sharing of individual data raises important social and ethical concerns. We examine ongoing development of one technology, DataSHIELD, which appears to elide privacy concerns about sharing data by enabling shared analysis while not actually sharing any individual-level data. We combine presentation of the development of DataSHIELD with presentation of an ethnographic study of a workshop to test the technology. DataSHIELD produced an application of the norm of privacy that was practical, flexible and operationalizable in researchers’ everyday activities, and one which fulfilled the requirements of ethics committees. We demonstrated that an analysis run via DataSHIELD could precisely replicate results produced by a standard analysis where all data are physically pooled and analyzed together. In developing DataSHIELD, the ethical concept of privacy was transformed into an issue of security. Development of DataSHIELD was based on social practices as well as scientific and ethical motivations. Therefore, the ‘success’ of DataSHIELD would, likewise, be dependent on more than just the mathematics and the security of the technology.
Practical radiation oncology | 2017
Philippe Laflamme; Cédric Doucet; Christian Sirois; N. Kopek; Marie Vanhuyse
Among germ cell tumors (GCTs), postpubertal primary mediastinal nonseminomatous germ cell tumors (PMNSGCTs) have the worse prognosis, with a 5-year survival rate of 45% to 50% in the most recent and largest series.1,2 This rare tumor represents only 1% of all primary mediastinal tumors, whereas only 1% to 5% of all GCTs are extragonadal, with the mediastinum being the most frequent location.2 As a result, dedicated literature on this specific subgroup of GCT is limited. The initial management of postpubertal PMNSGCT is similar to metastatic testicular nonseminomatous GCT (NSGCT) and includes cisplatin-based chemotherapy and surgery.2 Rates of chemotherapy refractory cases and early progressions seem to be more elevated in PMNSGCT and lead to a worse prognosis.3 Use of ablative radiation therapy (RT) in that context is not well described in the literature.
Human Genetics | 2007
George Zogopoulos; Kevin C.H. Ha; Faisal Naqib; Sara Moore; Hyeja Kim; Alexandre Montpetit; Frédérick Robidoux; Philippe Laflamme; Michelle Cotterchio; Celia M. T. Greenwood; Stephen W. Scherer; Brent W. Zanke; Thomas J. Hudson; Gary D. Bader; Steven Gallinger
PLOS Genetics | 2005
Alexandre Montpetit; Mari Nelis; Philippe Laflamme; Reedik Mägi; Xiayi Ke; Maido Remm; Lon R. Cardon; Thomas J. Hudson; Andres Metspalu
Stat | 2013
Elinor M. Jones; Nuala A. Sheehan; Amadou Gaye; Philippe Laflamme; Paul R. Burton